Compare Immunovant Inc. Common Stock (IMVT) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Opendoor Technologies Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.3 (market cap $6.25B), while Opendoor Technologies Inc trades at $2.22 (market cap $2.22B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.8× Opendoor Technologies Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Opendoor Technologies Inc for 33 Days on average.
| IMVT | OPEN | |
|---|---|---|
Market Cap | $6.25B | $2.22B |
Volume | 1,755,411 | 28,705,892 |
Sector | Health | Real Estate |
52-Week High | $44.96 | $9.37 |
52-Week Low | $17.03 | $2.27 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.35B | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Opendoor Technologies (OPEN) trades at $2.27 with no recent price movement, reflecting ongoing investor caution. The stock shows bearish technical signals with most moving averages and oscillators indicating selling pressure. Fundamentally, the company continues to struggle with profitability, posting a -46.74% net income margin and -$1.30B net loss in 2025 despite $4.37B revenue. Recent news highlights the company's mortgage expansion strategy and ongoing challenges in the housing market.
While analyst consensus suggests significant upside potential with a $4.92 price target, the company faces substantial execution risks amid persistent losses and high debt levels. The path to profitability remains uncertain, with revenue declining from $15.6B in 2022 to $4.4B in 2025. Investors should weigh the discounted valuation against ongoing operational challenges in the volatile housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
